Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.88 million shares were traded. CLNE stock price reached its highest trading level at $2.29 during the session, while it also had its lowest trading level at $2.24.
Ratios:
Our goal is to gain a better understanding of CLNE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.74. For the most recent quarter (mrq), Quick Ratio is recorded 2.39 and its Current Ratio is at 2.69. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.64.
On October 03, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $6.
On September 05, 2023, Northland Capital started tracking the stock assigning a Outperform rating and target price of $7.50.Northland Capital initiated its Outperform rating on September 05, 2023, with a $7.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 18 ’25 when Corbus Barclay sold 105,300 shares for $2.63 per share. The transaction valued at 276,928 led to the insider holds 1,061,248 shares of the business.
Corbus Barclay bought 105,300 shares of CLNE for $276,700 on Sep 18 ’25. On Aug 14 ’25, another insider, Littlefair Andrew J, who serves as the CEO AND PRESIDENT of the company, sold 250,000 shares for $2.25 each. As a result, the insider received 562,500 and left with 1,494,637 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLNE now has a Market Capitalization of 493427232 and an Enterprise Value of 648664256. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.16 while its Price-to-Book (P/B) ratio in mrq is 0.84. Its current Enterprise Value per Revenue stands at 1.538 whereas that against EBITDA is 99.887.
Stock Price History:
The Beta on a monthly basis for CLNE is 2.11, which has changed by -0.12109375 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, CLNE has reached a high of $3.67, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is -8.73%, while the 200-Day Moving Average is calculated to be 5.70%.
Shares Statistics:
The stock has traded on average 1.36M shares per day over the past 3-months and 992040 shares per day over the last 10 days, according to various share statistics. A total of 219.29M shares are outstanding, with a floating share count of 141.04M. Insiders hold about 35.68% of the company’s shares, while institutions hold 45.95% stake in the company. Shares short for CLNE as of 1764288000 were 8215693 with a Short Ratio of 6.05, compared to 1761868800 on 7946838. Therefore, it implies a Short% of Shares Outstanding of 8215693 and a Short% of Float of 5.050000000000001.
